Quarterly report · Q1

Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.4bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥18.0bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.8bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.6bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥439.6bnat 2023-06-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥357.5bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥110.9bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥328.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥316.8bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥130.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥12.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥16.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥18.292023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥18.272023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥167m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥16m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥114m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-06-30¥21.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-06-30¥21.1bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥868m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥11m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
—segment totalrevenue2023-04-01 → 2023-06-30¥57.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.0bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥18.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 587
ItemContextValueUnit
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember45100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember678776100
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember6787761
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember142900
Number of shares issued shares voting rightsCurrentQuarterInstant678964100
Number of voting rights issued shares voting rightsCurrentQuarterInstant6787761
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member45100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member45100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0001
Number of shares held in own name treasury shares etcCurrentQuarterInstant45100
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant45100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0001
Cash and cash equivalents IFRSPrior1YearInstant118319000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant130739000000JPY
Trade and other receivables ca IFRSPrior1YearInstant50537000000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant48776000000JPY
Other financial assets ca IFRSPrior1YearInstant28069000000JPY
Other financial assets ca IFRSCurrentQuarterInstant31337000000JPY
Other current assets ca IFRSPrior1YearInstant6546000000JPY
Other current assets ca IFRSCurrentQuarterInstant17944000000JPY
Current assets IFRSPrior1YearInstant203471000000JPY
Current assets IFRSCurrentQuarterInstant228795000000JPY
Property plant and equipment IFRSPrior1YearInstant19034000000JPY
Property plant and equipment IFRSCurrentQuarterInstant21349000000JPY
Goodwill IFRSPrior1YearInstant71342000000JPY
Goodwill IFRSCurrentQuarterInstant76726000000JPY
Intangible assets IFRSPrior1YearInstant40711000000JPY
Intangible assets IFRSCurrentQuarterInstant42929000000JPY
Investments accounted for using equity method IFRSPrior1YearInstant46122000000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant47808000000JPY
Financial assets measured at fair value nca IFRSPrior1YearInstant10527000000JPY
Financial assets measured at fair value nca IFRSCurrentQuarterInstant11162000000JPY
Other financial assets nca IFRSPrior1YearInstant2555000000JPY
Other financial assets nca IFRSCurrentQuarterInstant2432000000JPY
Deferred tax assets IFRSPrior1YearInstant2420000000JPY
Deferred tax assets IFRSCurrentQuarterInstant2395000000JPY
Other non current assets nca IFRSPrior1YearInstant4463000000JPY
Other non current assets nca IFRSCurrentQuarterInstant6044000000JPY
Non current assets IFRSPrior1YearInstant197174000000JPY
Non current assets IFRSCurrentQuarterInstant210845000000JPY
Assets IFRSPrior1YearInstant400645000000JPY
Assets IFRSCurrentQuarterInstant439640000000JPY
Trade and other payables cl IFRSPrior1YearInstant32864000000JPY
Trade and other payables cl IFRSCurrentQuarterInstant33734000000JPY
Income taxes payable cl IFRSPrior1YearInstant9831000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant5769000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass